

September 30, 2024
Fuji Pharma Co., Ltd.

**Submission of a Marketing Approval Application for the 2nd Biosimilar Product
Developed under Alvotech Partnership**

Tokyo, Japan - Fuji Pharma Co., Ltd. ("Fuji") has announced that Fuji has submitted an application for marketing approval of biosimilar product for the Japanese market developed under the exclusive development and commercialization partnership with Alvotech (Head Office: Iceland) to the Ministry of Health, Labor and Welfare (MHLW).

On November 16, 2018, Fuji and Alvotech announced "[ALVOTECH AND FUJI PHARMA ENTER INTO EXCLUSIVE PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF BIOSIMILARS IN JAPAN](#)", after Fuji and Alvotech agreed to form an exclusive partnership for development and commercialization of biosimilars in Japan. This marks the second biosimilar product developed under the Fuji-Alvotech partnership, with "Ustekinumab BS 45mg Syringe for S.C. Injection F" (Ustekinumab(Genetical Recombination)[Ustekinumab Biosimilar 1]) being the first product receiving marketing approval in May 2024. ,

Fuji Pharma remains committed to expediting the approval process and bringing life-saving biosimilars to patients across Japan, ensuring faster access to affordable treatments while maintaining the highest standards of quality and safety..

Note

The financial forecasts and other projections provided in this release are based on information available at the time of its compilation and it therefore contains an element of uncertainty and potential risks. Actual results may differ significantly from these forecasts for a number of reasons. It should also be noted that the views and/or facts presented here may be altered or deleted without prior notification. Information in this release about pharmaceuticals (including items in the pipeline) is not provided for the purpose of marketing or advertising or of supplying medical advice.

For further information, contact

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

fsks@fujipharma.jp